全球制药巨头阿斯利康周四表示，将开始销售一种抗癌药物，此前该公司因未能更快将其推向美国市场而受到批评，导致一些美国人飞往上海采购这种由中国首创、可能挽救生命的药物。
Global pharmaceutical firm AstraZeneca said on Thursday it would start selling a cancer drug after coming under criticism for failing to bring it to the US market faster, prompting some Americans to fly to Shanghai to procure the potentially life-saving medicine first developed by China.
据一位癌症治疗倡导者透露，他在母亲患病期间曾前往中国，近几个月来，绝望的美国人前往中国获取这种中国制造的抗癌药物，该药已获美国食品药品监督管理局（FDA）批准，但在美国却无法获得长达一年多。
In recent months, desperate Americans have travelled to China to obtain the Chinese-made cancer drug that was approved by the US Food and Drug Administration but remained unavailable in the country for more than a year, according to a cancer-treatment awareness advocate who made the journey while his mother was battling the disease.
这种名为舒沃替尼的靶向肺癌药物由中国的迪哲医药开发，旨在治疗患有晚期肺癌的成年人，为患者提供了另一种治疗选择。
Developed by China’s Dizal Pharmaceutical, sunvozertinib is a targeted lung cancer drug designed to treat adults with an advanced form of the illness, offering another treatment option for patients.
“该药于2023年在中国获批。FDA于2025年7月批准了它，”连接癌症患者与临床试验的咨询公司Patient Data Vault首席执行官马克斯·多佩尔特周三在社交媒体上写道。
“The drug was approved in China in 2023. The FDA approved it in July 2025,” Max Doppelt, chief executive of Patient Data Vault, a consultancy that connects cancer patients to clinical trials, wrote on social media on Wednesday.
“我知道至少有30名美国人进行了同样的旅行。”多佩尔特表示，他在2025年1月飞往上海获取该药物，此前他母亲的肺癌已扩散至大脑。
“I know of at least 30 Americans who have made the same trip.”Doppelt said that he travelled to Shanghai in January 2025 to obtain the drug after his mother’s lung cancer spread to her brain.
“一位医生几乎是顺口一提，说如果她是中国人，就能在药店买到。”
“A doctor told me, almost as an aside, that if she were Chinese she could buy it at a pharmacy.
“所以我飞往上海，行李里带回了26盒。那是19个月前的事了。我妈妈还在，还在工作，用她的话说，这三年过得很精彩。”多佩尔特补充说，他一直不愿分享经历，担心会危及母亲获取药物的途径。
“So I flew to Shanghai and came home with 26 boxes in my luggage. That was 19 months ago. My mom is still here, still working, and in her words has had an amazing three years.”Doppelt added he had been reluctant to share his experience for fear of jeopardising his mother’s access to the medicine.
“但问题比我的沉默更重要。这些药物需要被开发并在这里上市，这意味着需要FDA改革，”他指出。《华盛顿邮报》周二首次报道了这一故事。
“But the problem matters more than my silence. These drugs need to be developed and available here, and that means FDA reform,” he noted. The Washington Post first reported the story on Tuesday.
阿斯利康周四表示，在从中国的德琪医药获得该药物的全球开发和销售权后，舒沃替尼将以品牌名 Zegfrovy 在美国上市销售。
AstraZeneca said on Thursday that sunvozertinib would be commercially available in the United States under the brand name Zegfrovy, after securing worldwide rights to develop and sell the drug from China’s Dizal Pharmaceutical.
虽然美国食品药品监督管理局（FDA）已于 2025 年 7 月授予该药物“加速批准”，但阿斯利康是在今年 7 月宣布与中国德琪医药达成“独家许可协议”。
While the FDA granted an “accelerated approval” to the drug in July 2025, AstraZeneca announced its “exclusive license agreement” with China’s Dizal Pharmaceutical in July of this year.
阿斯利康在一份新闻稿中表示：“阿斯利康将获得 Zegfrovy 的全球开发和商业化权利。”阿斯利康未立即回应置评请求。
“AstraZeneca will acquire worldwide rights to develop and commercialise Zegfrovy,” the company said in a press release. AstraZeneca did not immediately respond to a request for comment.
该交易包含向德琪医药支付 6 亿美元的首付款，若满足特定监管批准条件，还可能支付高达 9 亿美元，此外还将就 Zegfrovy 的全球销售支付分级特许权使用费。
The deal included a US$600 million upfront payment to Dizal, with a further US$900 million potentially payable upon meeting specific regulatory clearances, as well as tiered royalties on global sales of Zegfrovy.
声明补充道：“预计交易将于 2026 年下半年完成，惟须满足惯例成交条件并获得监管批准。”
“The transaction is expected to close in the second half of 2026, subject to customary closing conditions and regulatory clearances,” the statement added.
科罗拉多大学的医学科学家凯尔·康卡农表示，华盛顿需要改变开发和采用新疗法的方式。
Kyle Concannon, a doctor-scientist at the University of Colorado, said Washington needed to change its approach to developing and adopting new treatments.
他在社交媒体上写道：“如果美国想保持竞争力，并确保患者不必环游世界寻求治疗，我们需要接受更大的风险，认识到对许多患者而言，替代方案是无药可医。”
“If the US wants to remain competitive and ensure patients don’t have to travel across the world for treatments, we need to both accept greater risk, recognising that for many patients the alternative is no treatment,” he wrote on social media.
23andMe 研究院首席执行官兼创始人安·沃伊西基指出，中国已从一个以生产原材料著称的国家，转变为药物发现领域的全球力量，这与美国在 2000 年代初的地位形成对比。
Anne Wojcicki, CEO and founder of the 23andMe Research Institute, noted that China had transformed from a country known for producing raw materials into a global force in drug discovery, contrasting its position with that of the US in the early 2000s.
她在社交媒体上表示：“世界已经翻转。中国成为药物发现强国并如今引领潮流，这令人惊叹。”
“The world has flipped. It’s remarkable how China has become a powerhouse in drug discovery and is now leading,” she said on social media.
她补充称，人工智能将给行业带来另一轮变革，大规模数据计划和“灵活的监管监督”将是推动进步的关键。
She added that artificial intelligence would bring another shift in the industry, with large-scale data initiatives and “nimble regulatory oversight” key to driving progress.
根据《英国医学杂志》编译的世界卫生组织数据，中国已迅速扩大其制药行业，在2024年1月至2025年6月期间，以占全球总数24%的份额领跑临床试验注册量。
China has rapidly expanded its pharmaceutical sector, taking the lead in clinical trial registrations between January 2024 and June 2025 with 24 per cent of the world total, according to World Health Organization data compiled by the British Medical Journal.
根据2026年3月发表在《美国医学会杂志》上的一项研究，中国在全球早期药物研发项目中的份额从2015年的8%上升至2024年的32%，缩小了与美国的差距；同期美国的份额从48%下降至37%。
China’s share of global early-stage drug-development programmes rose from 8 per cent in 2015 to 32 per cent in 2024, closing the gap with the US, whose share fell from 48 per cent to 37 per cent over the same period, according to a study published in the Journal of the American Medical Association in March 2026.